MAXIND

Max India Share Price

₹194.25 +0.94 (0.49%)

02 May, 2025 13:50

SIP TrendupStart SIP in MAXIND

Start SIP

Performance

  • Low
  • ₹188
  • High
  • ₹196
  • 52 Week Low
  • ₹160
  • 52 Week High
  • ₹319
  • Open Price₹193
  • Previous Close₹193
  • Volume84,058

Investment Returns

  • Over 1 Month + 10.73%
  • Over 3 Month -20%
  • Over 6 Month -25.71%
  • Over 1 Year -22.77%
SIP Lightning

Smart Investing Starts Here Start SIP with Max India for Steady Growth!

Invest Now

Max India Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -8.7
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 1,008
  • P/B Ratio
  • 1.8
  • Average True Range
  • 12.69
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 4.27
  • RSI
  • 49.71
  • MFI
  • 72.53

Max India Financials

Max India Technicals

EMA & SMA

Current Price
₹194.25
+ 0.94 (0.49%)
pointer
  • stock-down_img
  • Bearish Moving Average 12
  • stock-up_img
  • Bullish Moving Average 4
  • 20 Day
  • ₹195.42
  • 50 Day
  • ₹196.92
  • 100 Day
  • ₹210.21
  • 200 Day
  • ₹220.23

Resistance and Support

196.7 Pivot Speed
  • R3 220.81
  • R2 213.90
  • R1 203.61
  • S1 186.41
  • S2 179.50
  • S3 169.21

What's your outlook on Max India?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Max India focuses on healthcare and senior living services, providing high-quality healthcare solutions through its network of hospitals and senior care facilities. It aims to enhance well-being and quality of life for individuals across India.

Max India has an operating revenue of Rs. 149.01 Cr. on a trailing 12-month basis. An annual revenue de-growth of -9% needs improvement, Pre-tax margin of -29% needs improvement, ROE of -11% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 1 which is a POOR score indicating inconsistency in earnings, a RS Rating of 23 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 23 indicates it belongs to a strong industry group of Medical-Hospitals and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Max India Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-04-15 Others Inter-alia, to consider 1. Proposal of Fund raising by way of equity shares or other securities of the Company through a rights issue and/or any other permissible mode. issue of equity shares of Rs. 10/- in the ratio of 19:100 @ premium of Rs. 140/-.
2025-02-06 Quarterly Results & Fund Raising
2024-10-24 Quarterly Results & Fund Raising
2024-08-14 Quarterly Results
2024-05-24 Audited Results

Max India F&O

Max India Shareholding Pattern

50.45%
0%
6.63%
0%
34.92%
8%

About Max India

  • NSE Symbol
  • MAXIND
  • BSE Symbol
  • 543223
  • Managing Director
  • Mr. Rajit Mehta
  • ISIN
  • INE0CG601016

Similar Stocks to Max India

Max India FAQs

Max India share price is ₹194 As on 02 May, 2025 | 13:36

The Market Cap of Max India is ₹1007.6 Cr As on 02 May, 2025 | 13:36

The P/E ratio of Max India is -8.7 As on 02 May, 2025 | 13:36

The PB ratio of Max India is 1.8 As on 02 May, 2025 | 13:36

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23